Evidence map›Paper›PMID 15699257›Full record

ArticleCirculation2005

Low plasma adiponectin levels predict progression of coronary artery calcification.

David M Maahs, Lorraine G Ogden, Gregory L Kinney, Paul Wadwa, Janet K Snell-Bergeon, Dana Dabelea, John E Hokanson, James Ehrlich, Robert H Eckel, Marian Rewers

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Circulation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01881828 phase3completedstarted 2013, after this paper: background citation

A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes

Ran2013Enrolled164Registered outcomes16Posted comparisons0ConditionsType 1 DiabetesArmsMetformin (glucophage), oral placebo
Open the trial in the graph
NCT02045290 phase3completedstarted 2014, after this paper: background citation

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

Ran2014Enrolled37Registered outcomes3Posted comparisons0ConditionsType 1 DiabetesArmsMetformin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 291 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Plasma adiponectin levels and clinical outcomes among haemodialysis patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2008
    Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Adipokines, adiposity, and atherosclerosis.Cellular and molecular life sciences : CMLS · 2022
    Review
  18. Review
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

David M MaahsBarbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 E 9th Ave, Denver, CO 80262, USA. David.Maahs@uchsc.edu
Lorraine G Ogden
Gregory L Kinney
Paul Wadwa
Janet K Snell-Bergeon
Dana Dabelea
John E Hokanson
James Ehrlich
Robert H Eckel
Marian Rewers
University of Colorado Health · US

Funding

ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KRUGMAN, RICHARD D. · 1985 to 2008
$52.6M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Training Program in Diabetes ResearchT32DK063687 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Andrea Steck · 2002 to 2026
$5.2M
NCRR NIH HHS M01 RR00051NHLBI NIH HHS R01 HL61753NIDDK NIH HHS P30 DK57516NIDDK NIH HHS T32 DK063687-03
6 · The paper itself

Abstract

backgroundCirculating adiponectin levels are lower in men than in women and lower in advanced coronary artery disease, obesity, and type 2 but not type 1 diabetes. However, it is not known whether low adiponectin levels predict development of atherosclerosis independently of other cardiovascular risk factors. METHODS AND

resultsProgression of coronary artery calcification (CAC) over an average of 2.6 years (range, 1.6 to 3.3) was assessed in a cohort of patients with type 1 diabetes and nondiabetic subjects 19 to 59 years of age. In this nested case-control substudy, plasma adiponectin levels were measured in 101 cases with significant CAC progression and in 205 controls. Controls were oversampled on the basis of age, gender, diabetes status, and presence of baseline CAC. In conditional logistic regression adjusted for baseline CAC volume and other significant predictors of CAC progression, adiponectin levels were inversely related to progression of CAC in diabetic (OR, 0.47; 95% CI, 0.24 to 0.94) and nondiabetic (OR, 0.15; 95% CI, 0.05 to 0.40 for a doubling in adiponectin levels) subjects. Adjustment for additional cardiovascular risk factors did not change this association. In conditional logistic regression models by quartiles of plasma adiponectin levels, the probability value for trend was statistically significant for all participants (P<0.001) and nondiabetic participants (P<0.001) and was borderline for type 1 diabetics (P=0.08).

conclusionsLow plasma adiponectin levels are associated with progression of CAC in type 1 diabetic and nondiabetic subjects independently of other cardiovascular risk factors.

Indexed as

AdiponectinAdultCalcinosisCase-Control StudiesCohort StudiesCoronary DiseaseDiabetes Mellitus, Type 1Disease ProgressionFemaleHumansIntercellular Signaling Peptides and ProteinsMaleMiddle AgedPredictive Value of TestsAdiponectinIntercellular Signaling Peptides and Proteins

Identifiers

PMID15699257
OpenAlexW2045599577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.